AVEO Pharmaceuticals, Inc. (AVEO) Given Average Recommendation of “Hold” by Brokerages
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been assigned an average rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $4.38.
Several equities analysts have commented on the stock. Seaport Global Securities restated a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Friday, October 6th. B. Riley started coverage on shares of AVEO Pharmaceuticals in a research report on Monday, November 13th. They set a “buy” rating and a $5.00 price objective for the company. started coverage on shares of AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, BidaskClub cut shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th.
AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $3.10 on Friday. The company has a market cap of $366.75, a price-to-earnings ratio of -4.37 and a beta of 1.14. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $4.24.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.